Mike Pearson: hard-driving boss Valeant boss ensured the group has, over the past eight years, bought one drug company after another. Photograph:  Scott Eells/Bloomberg

What is the right way to build up a drug company? Do you take the traditional route, investing in your own research and development and seeking to dis(...)

Gains at Airbus  and Renault  helped European stocks record their best month in more than six years yesterday.  Photographs: Pascal Rossignol.

European stocks recorded their best month in more than six years yesterday, buoyed by gains at carmaker Renault and aircraft maker Airbus while inves(...)

Michael Pearson, chairman of the board and chief executive officer of Valeant Pharmaceuticals: His methods  proved he didn’t have much patience for research and development. Photograph: Christinne Muschi/Reuters

Valeant Pharmaceuticals is a sleazy company. Although it existed before 2010, it did a deal that year that put it on the map. The deal was with Biovai(...)

Building materials group CRH gained 1.54% to close at €24.685 on trades totalling more than 800,000 shares

Markets surged yesterday after European Central Bank (ECB) president Mario Draghi signalled that its stimulus programme would continue well into next (...)

Valeant shares fell the most in four years after politicians asked to subpoena the company for documents relating to drug price increases

Valeant Pharmaceuticals continued to lose ground yesterday after the company was targeted by US Democrats over rising drug prices. Valeant shares shed(...)

Under Hillary Clinton’s plan, the $250 monthly cap would limit what insurance companies could ask patients to pay for drugs that treat patients with chronic or serious medical conditions. Photograph: CBS News/Reuters

US Democrat presidential candidate Hillary Clinton on Tuesday will propose a $250 (€225) monthly cap on prescription drugs to stop what she calls “exc(...)

The drug could cost women as much as $400 per month

Valeant Pharmaceuticals agreed to pay about $1 billion (€895 million) in cash for Sprout Pharmaceuticals, the US pharmaceutical group that this week r(...)

Valeant Pharmaceuticals, the Canadian drugmaker known for its serial acquisitions, reported first-quarter profit that topped analysts’ estimates and r(...)

Teva factory sign on its plant in Jerusalem: Teva says its stock-and-cash offer of $82 a share represented a 48 per cent premium to Mylan’s stock price on March 10th, which it said was the last day of trading prior to the widespread speculation. Photograph: Menahem Kahana

Generic drugmaker Teva Pharmaceutical Industries Ltd yesterday proposed buying Mylan for $40 billion, saying it was a better deal than the smaller riv(...)

In Dublin Ryanair rose by more than 1.3 per cent as investors greeted the news that its board has ratified a push into the transatlantic market in coming years

Germany’s Dax raced to record highs on Monday, part of an extended rally of the European stock market driven by investors’ expectations that a weaken(...)